Literature DB >> 12183087

Dexmedetomidine: a new option for intractable distress in the dying.

Luiz Guilherme L Soares, Cláudia Naylor, Maurílio A Martins, Geralda Peixoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12183087     DOI： 10.1016/s0885-3924(02)00423-2

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  4 in total

1.  Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers.

Authors:  P Uusalo; D Al-Ramahi; I Tilli; R A Aantaa; M Scheinin; T I Saari
Journal:  Eur J Clin Pharmacol       Date:  2018-04-17       Impact factor: 2.953

2.  Applications of Dexmedetomidine in Palliative and Hospice Care.

Authors:  Rafael Lemus; Natalie L Jacobowski; Lisa Humphrey; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2022-09-26

3.  A new approach to the prevention and treatment of delirium in elderly patients in the intensive care unit.

Authors:  Andrew B Rosenzweig; Charmian D Sittambalam
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-09-01

4.  Dexmedetomidine for Sedation during Withdrawal of Support.

Authors:  Chris O'Hara; Robert F Tamburro; Gary D Ceneviva
Journal:  Palliat Care       Date:  2015-08-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.